Pharmafile Logo
Pharmafocus logo
Advanced Search

Lundbeck

Showing 15 posts of 69 posts found.

Lundbeck sells $100m portfolio

January 22, 2013
Sales and Marketing Lundbeck, OTC, Panhematin, Recordati

Italian pharma group Recordati has paid $80 million to Lundbeck for a portfolio of products primarily aimed at the US …

News
screen_shot_2013-01-11_at_09

Lundbeck appoints new global pricing and market access VP

January 11, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eggert, Jaszewski, Lundbeck

Barbara Jaszewski, has been appointed vice president of global pricing and market access at Lundbeck. She will be in charge …

Appointment
Lundbeck plant image

Lundbeck opens first Asian manufacturing plant

November 14, 2012
Manufacturing and Production China, Lundbeck

Lundbeck has officially opened its first manufacturing facility in China and says it plans to launch three new drugs there …

News

API supply issues lead Lundbeck to drop cancer drug

September 18, 2012
Manufacturing and Production Elspar, Lundbeck, Ovation

Danish firm Lundbeck has decided to discontinue supplies of its leukaemia drug Elspar from December after struggling to find a …

News
screen_shot_2012-08-22_at_09

Lundbeck makes two senior appointments

August 22, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andreas Eggert, Klaus Abel, Lundbeck

Lundbeck has appointed Andreas Eggert (pictured) as senior vice president for global product strategy, and Klaus Abel as vice president …

Appointment

Ireland agrees deal on medicines

June 28, 2012
Business Services, Sales and Marketing AstraZeneca, IPHA, Ireland, Lundbeck, Novartis, pricing

Ireland’s pharmaceutical industry has agreed a deal with the country’s government which breaks a deadlock over prices and access. The …

News

Lundbeck to slash 600 jobs in Europe

June 15, 2012
Sales and Marketing Cipralex, Europe, Lundbeck, austerity, cuts

Lundbeck will cut 600 jobs from its operations in Europe as its Cipralex parent expiry continues to erode revenue. The …

News

Lundbeck’s Alzheimer’s drug shows promise

May 29, 2012
Research and Development, Sales and Marketing Alzheimer's, Lundbeck

Lundbeck’s Alzheimer’s candidate Lu AE58054 has shown signs in a phase II study of helping patients’ mental activity. Sufferers receiving …

News
Michael Quiqueran-Beaujeu (left) and João Rocha

Lundbeck appoints European leaders

February 10, 2012
Medical Communications, Sales and Marketing Cipralex, Lundbeck

Lundbeck has appointed two new regional vice presidents for European markets, in time for new drug launches.João Rocha is to …

News

Lundbeck gets award for manufacturing excellence

January 18, 2012
Manufacturing and Production Lundbeck, Shingo, manufacturing

Efforts by Lundbeck to boost the productivity of its manufacturing operations have borne fruit, with the company cutting costs by …

News

Lundbeck launches bipolar drug Sycrest in the UK

January 17, 2012
Sales and Marketing Lundbeck, Saphris, Sycrest, zyprexa

Lundbeck has launched Sycrest in the UK for the treatment of acute attacks of bipolar I disorder. Sycrest (asenapine) is …

News

Otsuka and UCB scale down collaboration

January 16, 2012
Research and Development, Sales and Marketing Lundbeck, Otsuka, UCB

Otsuka and UCB have scaled back the scope of their collaboration, and will now focus on developing drugs for the …

News

Lundbeck and Otsuka to collaborate in CNS

November 11, 2011
Research and Development, Sales and Marketing Abilify, CNS, Lundbeck, Otsuka

Lundbeck and Otsuka have signed a major collaborative deal to sell and develop up to five CNS drugs, including a …

News
picture_2

Lundbeck appoints two new R&D vice presidents

November 1, 2011
Research and Development Lundbeck, R&D

Lundbeck has appointed Jens Peter Balling and Iman Barilero as vice presidents of its research and development organisation. The new …

Appointment
Lundbeck headquarters, Denmark

Lundbeck establishes research centre in China

October 18, 2011
Research and Development Brain disorders, CNS, China, Lundbeck, Shanghai, emerging markets

Lundbeck has set up a new research centre in China, joining a wave of pharma companies investing in the region. The …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025